Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
NCT06087068Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of levothyroxine sodium in Papillary Thyroid Carcinoma (PTC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Recurrence at 2 years. Started Aug 2022; status: recruiting.
02
Drugs
levothyroxine sodium
03
Conditions
Papillary Thyroid Carcinoma (PTC)
Beyond the preview
Go deeper on NCT06087068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087068.